Publicacións en colaboración con investigadores/as de Radboud University Nijmegen Medical Centre (14)

2023

  1. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

    Journal of Rheumatology, Vol. 50, Núm. 8, pp. 1009-1019

2021

  1. Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts

    Frontiers in Immunology, Vol. 12

2020

  1. NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Correction: Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients (The Pharmacogenomics Journal, (2019), 19, 1, (83-96), 10.1038/s41397-018-0057-x)

    Pharmacogenomics Journal

  2. Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients

    Pharmacogenomics Journal, Vol. 19, Núm. 1, pp. 83-96

  3. Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium

    Scientific Reports, Vol. 9, Núm. 1

2016

  1. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration

    Arthritis Research and Therapy, Vol. 18, Núm. 1

  2. Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration [Arthritis Res Ther. 18: (2016); 50], doi: 10.1186/s13075-016-0951-z

    Arthritis Research and Therapy

2012

  1. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: Results of a 1-year follow-up study from the CERERRA collaboration

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 3, pp. 374-377

2011

  1. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: Pooled data from 10 European registries

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 9, pp. 1575-1580

2010

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 6, pp. 964-975

2008

  1. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients withd-heumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 67, Núm. 10, pp. 1365-1373

  2. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

    Arthritis Care and Research, Vol. 59, Núm. 10, pp. 1371-1377

  3. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

    Annals of the Rheumatic Diseases, Vol. 67, Núm. 10, pp. 1360-1364